Inactive Instrument
Sector dividends Plasmatech Biopharmaceuticals Inc Nasdaq
Stocks
US72754H1095
Pharmaceuticals
|
End-of-day quote
Nasdaq
|
||
| - USD | - |
|
| 14/08 | Oppenheimer Adjusts PT on Abeona Therapeutics to $21 From $22, Maintains Outperform Rating | MT |
| 14/08 | Abeona Therapeutics Shares Fall After Q2 Miss | MT |
Main competitors
| Dividend Yield (Y) | Dividend Yield (Y+1) | P/E (Y) | Price to Book (Y) | EV / Sales (Y) | EV / EBITDA (Y) | EV / EBIT (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|---|---|---|
| 0.47% | 0.54% | 19.19x | 2.53x | 4.48x | 10.56x | 12.43x | 8.27TCr | ||
| -.--% | -.--% | -16.19x | 9.81x | 24.59x | -15.87x | -14.8x | 5.54TCr | ||
| 2.49% | 2.63% | 19.91x | 3.54x | 4.26x | 13.15x | 15.13x | 5.79TCr | ||
| -.--% | -.--% | 38.27x | 7.88x | 13.07x | 25.07x | 29.11x | 5.26TCr | ||
| 0.66% | 0.68% | 22.03x | 3.48x | 4.86x | 13.87x | 17.24x | 4.89TCr | ||
| -.--% | -.--% | 38.76x | 1.74x | 3.56x | 13.56x | 14.78x | 3.22TCr | ||
| -.--% | -.--% | 57.11x | 4.37x | 3.65x | 28.31x | 25.13x | 2.59TCr | ||
| -.--% | -.--% | 73.65x | 6.64x | 7.15x | 47.83x | 57.63x | 2.21TCr | ||
| -.--% | -.--% | 23.69x | 3.48x | 5.09x | 13.26x | 18.43x | 1.65TCr | ||
| 0.15% | 0.14% | 75.27x | 30.76x | 45.35x | 65.86x | 68.38x | 1.61TCr | ||
| -.--% | -.--% | -29.51x | -5.89x | 16.73x | -44.59x | -45.21x | 1.58TCr | ||
| -.--% | -.--% | 22.26x | - | 3.76x | 14.67x | 18.6x | 1.26TCr | ||
| -.--% | -.--% | -76.79x | 135.7x | 10.97x | -78.81x | -78.45x | 1.08TCr | ||
| -.--% | -.--% | 45.08x | - | - | - | - | 1.01TCr | ||
| 2.79% | 3.05% | 12.58x | 1.17x | 1.88x | 7.63x | 10.08x | 693.92Cr | ||
| -.--% | -.--% | 62.9x | 7.56x | 6.12x | 33.89x | 45.65x | 619.35Cr | ||
| 0.37% | 0.43% | 28.18x | - | 7.57x | 20.07x | 23.97x | 579.62Cr | ||
| Average | 0.41% | 0.44% | 24.49x | 15.20x | 10.19x | 10.53x | 13.63x | 2.82TCr | |
| Weighted average by Cap. | 0.5% | 0.54% | 22.93x | 8.52x | 9.85x | 11.25x | 13.73x |
Select your edition
All financial news and data tailored to specific country editions
















